Background
==========

Over the last decade, we have shown that cGMP, derived from bradykinin, nitric oxide (NO^•^, both from endogenous and exogenous sources) or natriuretic peptides, is a potent inhibitor of cardiac hypertrophy, across isolated cardiomyocytes and intact hearts both *ex vivo*and *in vivo*. However, NO• bioavailability is reduced due to scavenging by ROS; furthermore, oxidation of sGC may result in sGC dysfunction (including loss of responsiveness to NO•). In the present study, we tested the hypothesis that the NO•-independent sGC stimulator BAY 41-2272 and the NO-independent sGC activator BAY 58-2667 elicit powerful antihypertrophic actions.

Materials and methods
=====================

Neonatal rat cardiomyocytes were incubated at 37°C in the presence of the hypertrophic stimulus, endothelin-1 (ET~1~, 60 nM) ± BAY 41-2272 or BAY 58-2667 (0.01--0.3 μM) for 48 h in serum-free conditions. Cardiomyocyte hypertrophy was assessed in live cells using conventional *in vitro*markers of hypertrophy, two dimensional area and cardiomyocyte *de novo*protein synthesis. Results were expressed as % paired control cardiomyocytes, mean ± SE.

Results
=======

See Table [1](#T1){ref-type="table"}.

###### 

sGC ligands inhibit cardiomyocyte hypertrophy

                                                                           Control    ET~1~alone   ET~1~+ BAY (0.01 μM)   ET~1~+ BAY (0.03 μM)   ET~1~+ BAY (0.10 μM)   ET~1~+ BAY (0.30 μM)
  ------------------------------------------------------------------------ ---------- ------------ ---------------------- ---------------------- ---------------------- ----------------------
  Cell size (% paired control cardiomyocytes, both n = 4)                                                                                                               
                                                                                                                                                                        
  BAY 41-2272                                                              100 ± 0%   146 ± 9%\*   128 ± 5%^\#^           116 ± 7%^\#^           106 ± 6%^\#^           108 ± 6%^\#^
  BAY 58-2667                                                              100 ± 0%   141 ± 8%\*   133 ± 11%              123 ± 7%^\#^           113 ± 2%^\#^           108 ± 12%
                                                                                                                                                                        
  *De novo*protein synthesis (% paired control cardiomyocytes, n = 5--6)                                                                                                
                                                                                                                                                                        
  BAY 41-2272                                                              100 ± 0%   122 ± 1%\*   102 ± 1%^\#^           101 ± 1%^\#^           102 ± 2%^\#^           110 ± 0%^\#^
  BAY 58-2667                                                              100 ± 0%   135 ± 2%\*   110 ± 3%               117 ± 3%               107 ± 2%^\#^           108 ± 3%

\*p \< 0.05 versus control; ^\#^p \< 0.05 versus ET~1~, on one-way RM. DMSO, the vehicle for the sGC ligands, had no effect on either parameter either alone, or in the presence of ET~1~.

Conclusion
==========

These results provide evidence that BAY 41-2272 and BAY 58-2667 elicit concentration-dependent inhibition of cardiac hypertrophy *in vitro*, in the absence of confounding haemodynamic factors and even at low (submicromolar) concentrations. These novel NO•-independent sGC ligands thus potentially may serve as useful antihypertrophic agents in patients, independent of blood pressure.
